GIV·IN PV GIVINOSTAT IN POLYCYTHEMIA VERA

Serial Number 79406926
Registration 7741742
700

Registration Progress

Application Filed
Feb 21, 2024
Under Examination
Approved for Publication
Feb 11, 2025
Published for Opposition
Feb 11, 2025
Registered
Apr 1, 2025

Trademark Image

GIV·IN PV GIVINOSTAT IN POLYCYTHEMIA VERA

Basic Information

Serial Number
79406926
Registration Number
7741742
Filing Date
February 21, 2024
Registration Date
April 1, 2025
Published for Opposition
February 11, 2025
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 1, 2025
Registration
Registered
Classes
035 041 042 045

Rights Holder

ITALFARMACO S.P.A.

99
Address
Viale Fulvio Testi, 330
I-20126 MILANO (MI)
IT

Ownership History

ITALFARMACO S.P.A.

Original Applicant
99
IT

ITALFARMACO S.P.A.

Owner at Publication
99
IT

ITALFARMACO S.P.A.

Original Registrant
99
IT

Legal Representation

Attorney
Cynthia A. Moyer

USPTO Deadlines

Next Deadline
1921 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20250401)
Due Date
April 01, 2031
Grace Period Ends
October 01, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

26 events
Date Code Type Description Documents
Nov 7, 2025 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Oct 17, 2025 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Oct 17, 2025 FIMP P FINAL DISPOSITION PROCESSED Loading...
Jul 2, 2025 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Apr 1, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Apr 1, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Feb 11, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 11, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 5, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 21, 2025 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 17, 2025 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jan 17, 2025 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jan 17, 2025 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jan 17, 2025 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Dec 4, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 3, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 3, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Nov 23, 2024 RFNT P REFUSAL PROCESSED BY IB Loading...
Nov 4, 2024 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Nov 4, 2024 RFRR P REFUSAL PROCESSED BY MPU Loading...
Oct 29, 2024 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Oct 28, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 19, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 18, 2024 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Oct 18, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 17, 2024 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 035
Management of business projects, namely management of clinical trial projects in the nature of providing information management services; recruitment and selection of personnel and experts for clinical trials; business management of clinical trials; outsourcing services in the nature of arranging service contracts for others in the field of pharmaceutical development and clinical research; records management services, namely indexing of documents for third parties, especially coordination and control of electronic and paper document flow; database management services in the field of pharmaceutical product development, namely, preparation of case report forms (CRFs); collection and compilation of data into a central storage in the field of clinical trials; compilation and provision of statistical and biostatistical information in the nature of statistical analysis and reporting services for business purposes; medical coding services for third parties, namely coding of clinical trial data for the purposes of medical science and of regulatory reviews and approvals in the nature of compilation and systemization of information into computer databases; compilation of data into computer databases for the purpose of medical science research and medical consultation; regulatory document submission management, namely compiling dossiers in electronic common technical document formats, annual reports, management of article submissions in the nature of records management services, namely document indexing for others.
Class 041
Education services, namely conducting seminars, conferences, workshops, and training sessions in the field of clinical trial management, pharmaceutical development, and regulatory compliance; training services in the field of clinical trial coordination, biostatistics, and data management; organization and execution of conventions, events, congresses, seminars, conferences, symposia, and exhibitions in the field of pharmaceutical and medical research; publication of texts, other than publicity texts; on-line publication of books and specialized magazines; multimedia publication of magazines, specialized magazines and newspapers; arranging and organization of meetings in the nature of seminars, workshops and social entertainment events, namely networking events in the field of pharmaceutical drug development and clinical research; regulatory document submission management, namely publishing presentations as printed matter.
Class 042
Scientific and technological services namely scientific research, analysis, testing, and data computer modeling services in the field of pharmaceutical development, clinical trials, and medical technology; scientific services and scientific research, namely conducting scientific pharmaceutical product feasibility studies and product designing medical devices and instruments for clinical trials; scientific services and product design, namely conducting scientific pharmaceutical product feasibility studies and designing medical devices and instruments for clinical trials; platform as a service (PAAS) comprising software platforms for the transmission of images, audiovisual content, video content and messages; scientific research for medical purposes; product research services, design and development of instruments for control and diagnostics; computer diagnostic services, computer system analysis services; scientific research; electronic data storage; technical writing, namely medical writing services for clinical protocols, study reports, and regulatory dossiers; providing online non-downloadable software featuring clinical study and clinical trial management system tools via a website; electronic storage of files and documents; providing online non-downloadable software providing access to study management files; programming of software for study management files and electronic storage services for archiving temporary files throughout the clinical study lifecycle; scientific research, namely programming of software for biostatistics, development of protocols for sample size and statistical power calculations, randomization plans, and statistical analysis plans; providing online non-downloadable software enabling interpretation and reporting of data for clinical trial reports and publications; product development for others; scientific research, namely intermediate analysis for early decision-making in clinical trials; providing online non-downloadable software for providing access to databases and data lists ready for a New Drug Application (NDA), regulatory submission-compliant data files, study data tabulation, and data on model regulatory submission standards; medical research and development for new products for others in the field of medical surveillance and safety plans; pharmaceutical drug development services; drug discovery services of adverse events from clinical trials; pharmaceutical drug development services, namely development of safety update reports, management safety plans, and medical surveillance plans; product quality testing of clinical trial's documentation, for example, standard operating procedures (SOPs) and work instructions, internal system reviews, site audits, provider evaluations; medical research in the field of pharmacology, namely study design optimization, and modeling of pharmacokinetic population and pharmacodynamic interactions; Information related to scientific and medical research in the area of clinical trials, namely the design of clinical trials and outcome measures for studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; Custom computer programming in the field of image training and integration into computer systems of suitability data with interactive response technology (IRT); Product design and development of computer databases for the collection, storage, management, analysis, and validation of data for use in the medical and pharmaceutical fields; Electronic data storage services for archiving presentations.
Class 045
Regulatory compliance consultancy, namely legal assistance to third parties in drafting and compiling applications for new drugs; legal services relating to the submission and lifecycle management of clinical trial applications to competent authorities, ethics committees, and regulatory agencies; legal assistance concerning the submission of amendments to applications for regulatory approval.

Additional Information

Design Mark
The mark consists of the wording "GIV IN PV" in capital letters, the parts "GIV" and "IN" being in green color separated by a full circle also in green color, the "PV" part being black in color, such parts being placed above the wording "GIVINOSTAT IN POLYCYTHEMIA VERA" in smaller size in black color except for the letters "GIV IN PV" in green color and being placed to the left of the entire wording are three elongated red ovals connected in the middle.
Color Claim
The colors green, red and black are claimed as a feature of the mark.

Classification

International Classes
035 041 042 045

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PV" and "GIVINOSTAT IN POLYCYTHEMIA VERA"